Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation

被引：3
|
作者：
Wood, Brian R. [1 ]
Kassaye, Seble G. [2 ]
Gerstoft, Jan [3 ]
机构：
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA USA
[2] Georgetown Univ, Dept Med, Washington, DC USA
[3] Univ Copenhagen, Dept Infect Dis, Rigshosp, Copenhagen, Denmark
来源：
AIDS | 2023年 / 37卷 / 04期
关键词：
RILPIVIRINE; FAILURE;
D O I：
10.1097/QAD.0000000000003476
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：689 / 691
页数：3
相关论文
共 50 条
  • [21] Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine
    Rubenstein, Emma
    Diemer, Myriam
    Goldwirt, Lauriane
    Lascoux-Combe, Caroline
    Chaix, Marie-Laure
    Rami, Agathe
    Ponscarme, Diane
    Lafaurie, Matthieu
    Denis, Blandine
    De Castro, Nathalie
    Gras, Julien
    Liegeon, Geoffroy
    Sellier, Pierre-Olivier
    Deville, Laure
    Chevret, Sylvie
    Delaugerre, Constance
    Molina, Jean-Michel
    AIDS, 2024, 38 (08) : 1267 - 1269
  • [22] A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
    Bares, Sara H.
    Scarsi, Kimberly K.
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 22 - 31
  • [23] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
    Orkin, C.
    Oka, S.
    Philibert, P.
    Brinson, C.
    Bassa, A. C.
    Gusev, D.
    Degen, O.
    Gonzalez Garcia, J.
    D'Amico, R.
    Dorey, D.
    Griffith, S.
    Margolis, D. A.
    St Clair, M.
    Williams, P.
    Spreen, W. R.
    HIV MEDICINE, 2020, 21 : 14 - 14
  • [24] Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV
    Taramasso, Lucia
    Bonora, Stefano
    Cingolani, Antonella
    Di Biagio, Antonio
    Gianotti, Nicola
    Guaraldi, Giovanni
    Lo Caputo, Sergio
    Madeddu, Giordano
    Maggi, Paolo
    Marchetti, Giulia
    Nozza, Silvia
    Rusconi, Stefano
    Maggiolo, Franco
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2025, 80 (03) : 610 - 623
  • [25] Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: Results from the Dutch ATHENA national observational cohort
    Jongen, V.
    Wit, F.
    van Eeden, A.
    Brouwer, A.
    Soetekouw, R.
    El Moussaoui, R.
    Stalenhoef, J.
    Sigaloff, K.
    Mudrikova, T.
    Gisolf, J.
    Wensing, A.
    van der Valk, M.
    HIV MEDICINE, 2023, 24 : 167 - 169
  • [26] Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start
    Pinto, Rogerio M.
    Hall, Evan
    Tomlin, Ryan
    JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2023, 34 (02): : 216 - 220
  • [27] Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine
    Rubenstein, E.
    Diemer, M.
    Goldwirt, L.
    Lascoux-Combe, C.
    Lafaurie, M.
    Ponscarme, D.
    Denis, B.
    De Castro, N.
    Rami, A.
    Sellier, P. -O.
    Deville, L.
    Chaix, M. -L.
    Delaugerre, C.
    Molina, J. -M.
    HIV MEDICINE, 2023, 24 : 481 - 482
  • [28] Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice
    Borghetti, Alberto
    Farinacci, Damiano
    Ciccullo, Arturo
    Dusina, Alex
    Moschese, Davide
    Iannone, Valentina
    D'Angelillo, Anna
    Lombardi, Francesca
    Delle Donne, Valentina
    Massaroni, Valentina
    Visconti, Elena
    Tamburrini, Enrica
    Di Giambenedetto, Simona
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (10) : 4970 - 4974
  • [29] Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
    Howe, Zach W.
    Norman, Sarah
    Lueken, Abbie F.
    Huesgen, Emily
    Farmer, Eric K.
    Jarrell, Kaitlyn
    Mathis, Joscelyn E.
    Bonham, Kyle W.
    Hahn, Julie
    PHARMACOTHERAPY, 2021, 41 (08): : 686 - 699
  • [30] Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European locations (CARISEL)
    Jonsson-Oldenbuettel, C.
    Ghosn, J.
    Sierra, J. Olalla
    van der Valk, M.
    Lutz, T.
    Belkhir, L.
    van Welzen, B. J.
    Hove, K.
    Ait-Khaled, M.
    DeMoor, R.
    Bontempo, G.
    Latham, C. L.
    Ngenzi, B.
    Okoli, C.
    Gutner, C. A.
    Iyer, S.
    Gill, M.
    Czarnogorski, M.
    D'Amico, R.
    van Wyk, J.
    HIV MEDICINE, 2023, 24 : 193 - 195
12345